Table 4.
Echocardiogram characteristics before, during, and after pembrolizumab-based combination therapy
| TTE characteristics | Baseline (n = 47) |
†During treatment (n = 47) |
‡p-value (vs. baseline) |
†Post-treatment (n = 30) |
‡p-value (vs. baseline) |
|---|---|---|---|---|---|
| E/E’, median (IQR) | 6.3 (5.1–7.7) | 6.8 (6.0-8.3) | 0.09 | 6.7 (5.2–7.8) | 0.82 |
| MWT (cm), mean (+/-SD) | 0.9 (0.2) | 0.9 (0.2) | 0.17 | 0.9 (0.2) | 0.82 |
| LVEF (%), median (IQR) | 64 (60–66) | 63 (58–66) | 0.10 | 63 (57–65) | 0.78 |
| LVEF ≤ 50% | 3 (5.9%) | 3 (6.4%) | > 0.99 | 2 (6.7%) | > 0.99 |
| Diastolic dysfunction | |||||
| Mild | 13 (26.0%) | 18 (43.9%) | > 0.99 | 11 (44.0%) | 0.50 |
| Moderate | 1 (2.0%) | 4 (9.8%) | > 0.99 | 3 (12.0%) | 0.25 |
| PASP (mmHg), mean (+/-SD) | 19.6 (5.4) | 20.2 (8.0) | 0.70 | 20.2 (5.1) | 0.73 |
| LAVI, median (IQR) | 17.7 (14.7–24.3) | 19.8 (15.6–24.4) | 0.85 | 24.4 (15.7–26.1) | 0.17 |
| GLS (%), mean (+/-SD) | -21.4 (2.3) | -19.2 (3.2) | 0.17 | -21.3 (3.2) | 0.16 |
| Valvular disease moderate | 1 (2.1%) | 3 (6.4%) | 0.25 | 2 (6.7%) | > 0.99 |
The most abnormal data obtained during treatment, and the most recent data obtained after treatment, are shown
Data are presented as number of patients (column %), mean (± SD), or median (IQR, interquartile range)
P-value is calculated by a paired t-test or signed rank test for continuous variables, and McNemar’s test for categorical variables
†Some variables may have smaller sample due to availability of reported parameter
‡Statistical analysis was done in patients with both baseline and post-treatment echocardiogram
Abbreviations: TTE, transthoracic echocardiogram; IQR, interquartile range; MWT, maximal wall thickness; SD, standard deviation; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure; LAVI, left atrial volume index; GLS, global longitudinal strain